135 related articles for article (PubMed ID: 1382552)
1. The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis.
Childs WJ; Nicholls EJ; Horwich A
Ann Oncol; 1992 Apr; 3(4):291-6. PubMed ID: 1382552
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors.
Horwich A; Dearnaley DP; Nicholls J; Jay G; Mason M; Harland S; Peckham MJ; Hendry WF
J Clin Oncol; 1991 Jan; 9(1):62-9. PubMed ID: 1702147
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.
Newell DR; Eeles RA; Gumbrell LA; Boxall FE; Horwich A; Calvert AH
Cancer Chemother Pharmacol; 1989; 23(6):367-72. PubMed ID: 2469544
[TBL] [Abstract][Full Text] [Related]
6. [Carboplatin-etoposide-bleomycine chemotherapy protocol in the treatment of patients with metastatic non-seminomatous germ-cell testicular tumours with good prognosis].
Jeremić B; Djurić Lj; Djordjević S; Cirović V; Milojević Lj; Stanisavljević B; Matović M; Mijatović Lj
Srp Arh Celok Lek; 1994; 122(9-10):257-9. PubMed ID: 17977429
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin dose in combination chemotherapy for testicular cancer.
Harland SJ; Gumbrell LA; Horwich A
Eur J Cancer; 1991; 27(6):691-5. PubMed ID: 1712607
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up.
Dearnaley DP; Horwich A; A'Hern R; Nicholls J; Jay G; Hendry WF; Peckham MJ
Eur J Cancer; 1991; 27(6):684-91. PubMed ID: 1712606
[TBL] [Abstract][Full Text] [Related]
9. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis.
Amato RJ; Ro JY; Ayala AG; Swanson DA
Urology; 2004 Jan; 63(1):144-8; discussion 148-9. PubMed ID: 14751368
[TBL] [Abstract][Full Text] [Related]
10. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
Tscherry G; Jacky E; Jost LM; Stahel RA
Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
[TBL] [Abstract][Full Text] [Related]
11. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin.
Brada M; Horwich A; Peckham MJ
Cancer Treat Rep; 1987 Jun; 71(6):655-6. PubMed ID: 2438041
[TBL] [Abstract][Full Text] [Related]
12. Use of carboplatin in germ cell tumors of the testis.
Horwich A; Mason M; Dearnaley DP
Semin Oncol; 1992 Feb; 19(1 Suppl 2):72-7. PubMed ID: 1329224
[TBL] [Abstract][Full Text] [Related]
13. Sequential trials of cisplatin, vinblastine, and bleomycin and etoposide and cisplatin in disseminated nonseminomatous germ cell tumors of the testis with a good prognosis at a single institution.
Germá JR; Sagarra AF; Izquierdo MA; Seguí MA
Cancer; 1993 Feb; 71(3):796-803. PubMed ID: 7679314
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of carboplatin dose escalation in combination chemotherapy with etoposide, bleomycin and GM-CSF support for poor prognosis nonseminomatous germ cell tumors patients.
Tjulandin SA; Stenina MB; Sidorova NJ; Delgado FG; Sokolov AV; Molchanov GV; Ljubimova NV; Garin AM
Neoplasma; 1996; 43(5):347-52. PubMed ID: 8996556
[TBL] [Abstract][Full Text] [Related]
15. Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy.
Gilbert DC; Norman AR; Nicholl J; Dearnaley DP; Horwich A; Huddart RA
BJU Int; 2006 Jul; 98(1):67-9. PubMed ID: 16831145
[TBL] [Abstract][Full Text] [Related]
16. Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial.
Pectasides D; Skarlos D; Dimopoulos AM; Farmakis D; Pectasides M; Fountzilas G; Aravantinos G
Anticancer Res; 2003; 23(5b):4239-44. PubMed ID: 14666633
[TBL] [Abstract][Full Text] [Related]
17. Does the number of cycles of cisplatin based chemotherapy have any effect on renal function in patients with testicular germ cell tumor?
Suer E; Mermerkaya M; Gülpınar Ö; Afandiyev F; Baltacı S; Türkölmez K; Bedük Y
J Urol; 2013 Dec; 190(6):2081-5. PubMed ID: 23764076
[TBL] [Abstract][Full Text] [Related]
18. High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours.
Kattan J; Mahjoubi M; Droz JP; Kramar A; Culine S; Boutan-Laroze A; Chazard M
Eur J Cancer; 1993; 29A(11):1504-9. PubMed ID: 8217352
[TBL] [Abstract][Full Text] [Related]
19. [Testicular malignant tumours. Efficacy of germ cell and sex cord tumours treatment protocol in Poland].
Popadiuk S; Korzon M; Chybicka A; Szmyd K; Dzierzega M; Trelińska J; Kowalczyk JR; Wiśniewska-Slusarz H; Woźniak W; Bilska K; Wachowiak J; Konatkowska B; Wysocki M; Krawczuk-Rybak M; Czauderna P; Szumera M; Sznurkowska K; Renke J
Med Wieku Rozwoj; 2006; 10(3 Pt 1):811-7. PubMed ID: 17317912
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
